US6653341B1
(en)
|
1998-06-17 |
2003-11-25 |
Eisai Co., Ltd. |
Methods and compositions for use in treating cancer
|
US8097648B2
(en)
*
|
1998-06-17 |
2012-01-17 |
Eisai R&D Management Co., Ltd. |
Methods and compositions for use in treating cancer
|
US6214865B1
(en)
|
1998-06-17 |
2001-04-10 |
Eisai Co., Ltd. |
Macrocyclic analogs and methods of their use and preparation
|
DE10037310A1
(de)
|
2000-07-28 |
2002-02-07 |
Asta Medica Ag |
Neue Indolderivate und deren Verwendung als Arzneimittel
|
AU2003224644A1
(en)
*
|
2002-02-27 |
2003-09-09 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan |
Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
|
PL219737B1
(pl)
|
2002-03-22 |
2015-07-31 |
Eisai R & D Man Co |
Pochodne hemiasterliny, środek farmaceutyczny i zastosowanie pochodnych i zastosowanie hemiasterliny
|
US20050075395A1
(en)
*
|
2003-05-28 |
2005-04-07 |
Gary Gordon |
Continuous dosing regimen
|
WO2004105794A2
(en)
*
|
2003-05-29 |
2004-12-09 |
Abbott Laboratories |
Continuous dosing regimen with abt-751
|
WO2005011589A2
(en)
*
|
2003-07-29 |
2005-02-10 |
Eisai Co., Ltd. |
Drug delivery methods and devices
|
CN109180615A
(zh)
*
|
2004-06-03 |
2019-01-11 |
卫材R&D管理有限公司 |
用于制备软海绵素b的类似物的中间体
|
EP2949652B1
(en)
|
2004-06-03 |
2019-08-07 |
Eisai R&D Management Co., Ltd. |
Intermediates for the preparation of halichondrin B
|
US20060045846A1
(en)
*
|
2004-08-30 |
2006-03-02 |
Horstmann Thomas E |
Reagents and methods for labeling terminal olefins
|
JP2008522623A
(ja)
*
|
2004-12-09 |
2008-07-03 |
エーザイ株式会社 |
ハリコンドリンbアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
|
EP2200992B1
(en)
|
2007-10-03 |
2014-02-26 |
Eisai R&D Management Co., Ltd. |
Intermediates and methods for the synthesis of halichondrin b analogs
|
CN105801599A
(zh)
*
|
2008-04-04 |
2016-07-27 |
卫材R&D管理有限公司 |
软海绵素b类似物
|
RU2476216C1
(ru)
*
|
2009-03-30 |
2013-02-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Липосомальная композиция
|
WO2010113983A1
(ja)
|
2009-03-30 |
2010-10-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
リポソーム組成物の製造方法
|
MX2011009632A
(es)
|
2009-03-30 |
2011-10-19 |
Eisai R&D Man Co Ltd |
Composicion de liposoma.
|
EP2420504B1
(en)
*
|
2009-04-14 |
2014-01-15 |
Nissan Chemical Industries, Ltd. |
Method for producing tetrahydropyran compound and intermediate thereof
|
US8203010B2
(en)
*
|
2010-01-26 |
2012-06-19 |
Eisai R&D Management Co., Ltd. |
Compounds useful in the synthesis of halichondrin B analogs
|
ES2731653T3
(es)
|
2011-03-18 |
2019-11-18 |
Eisai R&D Man Co Ltd |
Métodos y usos para predecir la respuesta a la eribulina
|
WO2012147900A1
(en)
|
2011-04-28 |
2012-11-01 |
Eisai R&D Management Co., Ltd. |
Microreactor process for halichondrin b analog synthesis
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
CN104053645A
(zh)
|
2011-11-30 |
2014-09-17 |
阿方拉研究股份有限公司 |
用于制备(3r)-2,4-二-离去基团-3-甲基丁-1-烯的工艺
|
US9174956B2
(en)
|
2011-12-16 |
2015-11-03 |
Alphora Research Inc. |
Process for preparation of 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives and intermediates useful thereof
|
WO2013097042A1
(en)
*
|
2011-12-29 |
2013-07-04 |
Alphora Research Inc. |
2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
|
IN2014MN02106A
(zh)
*
|
2012-03-30 |
2015-09-11 |
Alphora Res Inc |
|
KR20150090921A
(ko)
|
2012-12-04 |
2015-08-06 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
유방암 치료에서 에리불린의 용도
|
AU2014268086A1
(en)
|
2013-05-15 |
2015-11-05 |
Alphora Research Inc. |
3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
|
RU2672585C2
(ru)
|
2013-06-26 |
2018-11-16 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака
|
JP6511613B2
(ja)
*
|
2013-07-03 |
2019-05-15 |
サンド・アクチエンゲゼルシヤフト |
ハリコンドリンBの大環状C1−ケト類似体の製造のための合成方法及び該方法に有用な中間体、例えば−SO2−(p−トリル)基を含有する中間体
|
CN103483352A
(zh)
*
|
2013-10-18 |
2014-01-01 |
李友香 |
抗肿瘤的药用原料药
|
EP3066102B1
(en)
|
2013-11-04 |
2020-02-26 |
Eisai R&D Management Co., Ltd. |
Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
|
SG10201805024YA
(en)
|
2013-12-06 |
2018-07-30 |
Eisai R&D Man Co Ltd |
Methods useful in the synthesis of halichondrin b analogs
|
CN104860978A
(zh)
*
|
2014-02-20 |
2015-08-26 |
正大天晴药业集团股份有限公司 |
软海绵素b类似物的合成中间体
|
TW201617326A
(zh)
|
2014-03-06 |
2016-05-16 |
Alphora研發股份有限公司 |
(s)-1-((2r,3r,4s,5s)-5-烯丙-3-甲氧-4-(對甲苯磺醯甲基)四氫呋喃-2-基)-3-氨基丙-2-醇之結晶衍生物
|
WO2015183961A1
(en)
|
2014-05-28 |
2015-12-03 |
Eisai R&D Management Co., Ltd |
Use of eribulin in the treatment of cancer
|
EP3160970A4
(en)
*
|
2014-06-30 |
2017-12-27 |
President and Fellows of Harvard College |
Synthesis of halichondrin analogs and uses thereof
|
KR102329681B1
(ko)
|
2014-08-28 |
2021-11-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
고순도의 퀴놀린 유도체 및 이를 제조하는 방법
|
WO2016038624A1
(en)
|
2014-09-09 |
2016-03-17 |
Cipla Limited |
"process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
|
CN105713031B
(zh)
*
|
2014-12-05 |
2021-05-07 |
正大天晴药业集团股份有限公司 |
一种用于制备艾日布林的中间体及其制备方法
|
BR112017017428A2
(pt)
|
2015-02-25 |
2018-04-03 |
Eisai R&D Management Co., Ltd. |
?método para supressão do amargor de derivado de quinolina?
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
EP3265122B1
(en)
*
|
2015-03-04 |
2022-05-04 |
Merck Sharp & Dohme Corp. |
Combination of pembrolizumab and eribulin for treating triple-negative breast cancer
|
WO2016176560A1
(en)
|
2015-04-30 |
2016-11-03 |
President And Fellows Of Harvard College |
Chromium-mediated coupling and application to the synthesis of halichondrins
|
CN117024469A
(zh)
|
2015-05-07 |
2023-11-10 |
卫材R&D管理有限公司 |
可用于合成软海绵素大环内酯的大环化反应以及中间体和其他片段
|
US10597401B2
(en)
|
2015-05-08 |
2020-03-24 |
Albany Molecular Research, Inc. |
Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
MX2018009794A
(es)
|
2016-02-12 |
2018-12-17 |
Eisai R&D Man Co Ltd |
Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
|
JP7015237B2
(ja)
|
2016-04-28 |
2022-02-02 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍の成長を抑制する方法
|
KR20190009326A
(ko)
*
|
2016-05-26 |
2019-01-28 |
닥터 레디스 레보러터리즈 리미티드 |
에리불린 및 그의 중간체의 제조방법
|
CN109641917B
(zh)
|
2016-06-30 |
2022-06-14 |
卫材R&D管理有限公司 |
可用于合成软海绵素大环内酯类及其类似物的普林斯反应和中间体
|
MX2019003994A
(es)
|
2016-10-14 |
2019-09-19 |
Merck Sharp & Dohme |
Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
|
JP6978758B2
(ja)
|
2016-11-11 |
2021-12-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
パラジウム媒介ケトール化
|
KR20190084065A
(ko)
|
2016-11-23 |
2019-07-15 |
닥터 레디스 레보러터리즈 리미티드 |
에리불린 및 그 중간체의 제조방법
|
KR101880939B1
(ko)
|
2017-01-02 |
2018-08-17 |
연성정밀화학(주) |
에리불린 메실산염의 제조 중간체 및 그의 제조방법
|
CN110139866B
(zh)
*
|
2017-01-02 |
2022-05-17 |
研成精密化学株式会社 |
用于制备甲磺酸艾日布林的中间体以及制备其的方法
|
KR101991710B1
(ko)
|
2017-12-14 |
2019-06-21 |
연성정밀화학(주) |
에리불린 메실산염의 제조 중간체 및 그의 제조방법
|
CN108341828B
(zh)
*
|
2017-01-24 |
2021-04-06 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的方法及其中间体
|
CN108341738B
(zh)
*
|
2017-01-24 |
2022-10-21 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的方法及其中间体
|
IL288991B2
(en)
|
2017-04-05 |
2023-12-01 |
Harvard College |
A macrocyclic compound and its uses
|
US9938288B1
(en)
|
2017-04-05 |
2018-04-10 |
President And Fellows Of Harvard College |
Macrocyclic compound and uses thereof
|
SG11201912342QA
(en)
|
2017-07-06 |
2020-01-30 |
Harvard College |
Synthesis of halichondrins
|
US11498892B2
(en)
|
2017-07-06 |
2022-11-15 |
President And Fellows Of Harvard College |
Fe/Cu-mediated ketone synthesis
|
US20190046513A1
(en)
|
2017-08-10 |
2019-02-14 |
Huya Bioscience International, Llc |
Combination therapies of hdac inhibitors and tubulin inhibitors
|
CN109694379B
(zh)
*
|
2017-10-24 |
2020-09-11 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的中间体及其制备方法
|
US11142509B2
(en)
|
2017-11-09 |
2021-10-12 |
Yonsung Fine Chemical Co., Ltd. |
Intermediate for preparing eribulin mesylate and process for preparing the same
|
EP3710454B1
(en)
|
2017-11-15 |
2024-01-03 |
President And Fellows Of Harvard College |
Macrocyclic compounds and uses thereof
|
EP3713565A1
(en)
|
2017-11-20 |
2020-09-30 |
Basilea Pharmaceutica International AG |
Pharmaceutical combinations for use in the treatment of neoplastic diseases
|
US11008296B2
(en)
|
2017-11-21 |
2021-05-18 |
Natco Pharma Limited |
Intermediates for the preparation of eribulin thereof
|
WO2019136145A1
(en)
|
2018-01-03 |
2019-07-11 |
Eisai R&D Management Co., Ltd. |
Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
|
WO2019211877A1
(en)
|
2018-05-03 |
2019-11-07 |
Cipla Limited |
Process for the preparation of macrocyclic ketone analogs of halichondrin b
|
WO2020008382A1
(en)
*
|
2018-07-04 |
2020-01-09 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of eribulin and intermediates thereof
|
JP2021532102A
(ja)
*
|
2018-07-20 |
2021-11-25 |
ドクター レディズ ラボラトリーズ リミテッド |
エリブリンおよびその中間体の調製のための精製プロセス
|
EP3864011A4
(en)
*
|
2018-10-09 |
2022-06-29 |
Dr. Reddy's Laboratories Ltd. |
Process for preparation of eribulin and intermediates thereof
|
US11447499B2
(en)
|
2019-06-14 |
2022-09-20 |
Rk Pharma Inc. |
Process for the preparation of eribulin mesylate intermediate
|
WO2020255164A1
(en)
|
2019-06-21 |
2020-12-24 |
Council Of Scientific And Industrial Research |
A chemo-enzymatic process for the preparation of homopropargylic alcohol
|
US12036204B2
(en)
|
2019-07-26 |
2024-07-16 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
WO2021090062A1
(en)
|
2019-11-07 |
2021-05-14 |
Eisai R&D Management Co., Ltd. |
Anti-mesothelin eribulin antibody-drug conjugates and methods of use
|
CN113135876B
(zh)
*
|
2020-01-16 |
2024-05-17 |
南通诺泰生物医药技术有限公司 |
艾日布林及其中间体的制备方法
|
CA3168654A1
(en)
*
|
2020-01-22 |
2021-07-29 |
Shanghai Senhui Medicine Co., Ltd. |
Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
|
KR102377262B1
(ko)
|
2020-05-11 |
2022-03-22 |
연성정밀화학(주) |
결정성 에리불린 염
|
IL279168B
(en)
*
|
2020-12-02 |
2022-04-01 |
Finetech Pharmaceutical Ltd |
A process for the preparation of eribulin
|
CN113354659B
(zh)
|
2021-06-08 |
2022-04-08 |
江苏慧聚药业股份有限公司 |
甲磺酸艾日布林的合成
|
TW202310878A
(zh)
*
|
2021-07-22 |
2023-03-16 |
大陸商上海森輝醫藥有限公司 |
艾日布林衍生物的藥物偶聯物
|
WO2023212746A2
(en)
*
|
2022-04-30 |
2023-11-02 |
William Marsh Rice University |
A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
|